Reporte zur Charge CEK4176

Symptomtext

Neurology issues; Severely Altered Mental Status; booster; This is a spontaneous report from a contactable consumer. A 50-year-old male patient received bnt162b2 (BNT162B2), dose 3 administered in Arm Left on 20Oct2021 16:30 (Batch/Lot number was not reported) at age of 50-year-old as DOSE 3 (BOOSTER), SINGLE for covid-19 immunisation. Facility type vaccine was Nursing Home/Senior Living Facility. Medical history included Asthma, Congestive Heart Failure, Traumatic brain injury (TBI). Prior to vaccination, the patient was diagnosed with COVID-19. Concomitant medications included influenza vaccine (FLU VACCINE VII) (lot number=308520) in arm on 05Oct2021 for immunisation; carvedilol; apixaban (ELIQUIS); famotidine; lactulose; montelukast; quetiapine; sertraline; simvastatin; tamsulosin; torsemide ; tramadol hydrochloride (TRAMADOC). The patient previously took first dose of bnt162b2 (Lot number: CEK 4176) in Left arm on 05Jan2021 at age of 50-year-old for covid-19 immunisation, second dose of bnt162b2 (Lot number:EN 5318) in Left arm on 05Feb202 at age of 50-year-old for covid-19 immunisation, morphine and experienced hypersensitivity. Evening of Booster, the patient experienced Severely Altered Mental Status and Neurology issues on 20Oct2021 11:00 PM. AE resulted in Emergency room/department or urgent care, Hospitalization for 7 days. AE treatment included 5 Psyche meds. The outcome was Not recovered. Covid test post vaccination Nasal Swab on 26Oct2021 with Negative result. Events were assessed serious as Medically Significant and hospitalization. The events occurred in a location different from that of the reporter. This may be a duplicate report if another reporter from the location where the event occurred has submitted the same information to his/her local regulatory agency. No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.